How to Get Epithalon: Every Route Ends in a 4.82 mg/mL Vial

Ordered from the route that asks most to the route that asks least. The last column is what you finish holding, which is where three of the four fall apart.

The pattern is unusual. Effort and outcome run in opposite directions here, which is not true of most controlled or prescription-only compounds, and it happens because the constraint is regulatory categorisation rather than scarcity. The same inversion shows up on our Selank routes page, where the neighbouring Russian peptide has exactly the same regulatory history.

This route is not difficult. It is unavailable, and the distinction matters because a great deal of search traffic is spent looking for the clinician who will say yes. No clinician can, and the reason sits in a document rather than in anyone's willingness.

There is no FDA-approved product containing this tetrapeptide, so there is nothing to prescribe directly. The compounding path is also closed: Epitalon appears on none of FDA's 503A category lists as of the update of 14 May 2026. It was nominated for compounding use, placed in category 2 under the interim policies, and then withdrawn by the nominator, leaving it on no current list. A compounding pharmacy needs a lawful bulk-substance basis, and a withdrawn nomination is not one.

The agency's substantive comment, worth reading once because it explains why a certificate matters more here than a discount:

Compounded drugs containing epitalon may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has not identified safety-related information regarding epitalon for the proposed route of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans.

Aggregation means peptide molecules clumping into larger assemblies. Peptide-related impurities are the truncated and modified sequences left behind by solid-phase synthesis. Neither is visible in a vial, both are measurable, and that is the entire case for weighting the analytical document heavily when you reach route four.

Longevity and anti-ageing practices do market this compound, so unlike most research peptides there is something real at the end of a local search. What they sell, though, is a bundle: assessment, consultation and a prepared preparation, invoiced as a programme rather than as a quantity.

For a site that divides things, that is where the route stops being analysable. A programme fee cannot be converted into dollars per milligram unless the practice publishes the mass it dispenses, and a mass without a lot code and a batch-specific certificate cannot be checked. Two questions settle it quickly, both worth asking in writing: what mass is being dispensed, and does a certificate exist for that lot.

There is a supply question underneath as well. With the bulk substance absent from every category list, a practice has no ordinary pharmacy channel, so the material originated somewhere the invoice does not describe. That is a question rather than an accusation, and it is the same question our NAD+ routes page works through for a compound where the clinic channel is far larger.

Ordering from an overseas seller looks like the cheapest route until you try to price it. Four costs sit behind the headline figure and none of them appears in the cart.

• Transit. Weeks rather than days, during which storage conditions are outside anyone's control. The lyophilised format is what makes this tolerable at all.
• Clearance. Duty and handling land after purchase, so the cart total is not the landed cost.
• Loss. A detained or returned parcel is a total write-off on that order, which turns a per-milligram figure into a probability rather than a price.
• Documentation. Most of these listings publish no lot-linked certificate, which removes purity, identity, contamination and net content in one stroke.

The fourth item is the one that ends the comparison. Without a measured net content there is no denominator, so the rate you calculate is derived from a label, and a label is a manufacturing target. A vial priced lower with nothing weighed is not cheaper per milligram; it is simply unpriced.

The route that asks least delivers most, which is the whole shape of this page. A domestic research-material supplier lists the 10 mg vial at $50.00, or $25.00 with the PEPTIDEDECK code, and publishes a Kovera Labs certificate for batch 15-05260628, report KVR-2026-A36FF4, certified 23 May 2026.

What that document contains, and what each row settles: purity of 99.312% against a stated minimum of 98%, measured by reversed-phase HPLC on a C18 column with detection at 214 nm; identity confirmed by LC-MS, which stops a purity figure from describing the wrong molecule; a net content of 9.64 mg against a specification of 10 mg plus or minus 10 percent; an endotoxin safety screen passing a 0.5 EU/mL limit; a sterility screen showing no growth; and arsenic, cadmium, lead and mercury all negative.

Two honest deductions. The endotoxin row prints PASS rather than a value in EU/mL and names no method, where the compendial reference for bacterial endotoxins testing is USP Chapter 85, so it tells you the sample was under a line without saying how far under. And only one certificate exists for this compound, where the neighbouring Russian peptides each carry two from two laboratories, so there is no second lot to compare against. Both matter, and neither changes that this is far more paper than most of this market publishes. The same document set is scored in detail on our Semax routes page.

The end of every route, expressed in the units a bench actually uses. Laboratory handling arithmetic only, and not guidance for administering anything to a person.

A U-100 syringe is graduated so that 100 units equal 1 mL. Add 2 mL of diluent and the label basis gives 5.00 mg/mL, making the whole vial 200 units of graduated volume, with 10 units carrying 500 mcg. On the certificate's 9.64 mg the same 2 mL gives 4.82 mg/mL and those 10 units carry 482 mcg, an 18 mcg shortfall that is exactly the 3.6 percent missing from the fill.

Five cents a portion is trivial. Knowing the number is not, because it is correctable: adding 1.93 mL instead of 2.00 mL restores a true 5.00 mg/mL, and nobody working from a label alone can make that adjustment. The conventions behind these figures are set out in our reconstitution guide.

Two closing limits. A certificate describes a sampled aliquot on a date, before filling and transit, so it is evidence about a batch rather than a promise about your vial. And the telomere and longevity claims that send people looking for this compound rest largely on work from a single research group, which explains the search volume rather than validating it.